The director general leaves his position at the European Federation of Pharmaceutical Industries and Associations (EFPIA) after five years to pursue “a fresh challenge.”
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced that its director general, Richard Bergström, is leaving the post.
“I am proud to leave EFPIA at a time when we have developed policies that promote innovation and patient access, such as through the focus on outcomes and on adaptive pathways to speed up the development of new medicines. After 15 fantastic years leading industry associations in Sweden and in Brussels, it is time for me to take on a fresh challenge,” he said.
Bergström succeeded Brian Ager as director general on April 1, 2011. He was previously director general of LIF, the Swedish research-based pharmaceutical industry association. He is a pharmacist by trade who worked for almost 20 years in the pharmaceutical industry, before moving to LIF in 2002.
Previously Bergström was chair of EFPIA’s Trust Committee and Task Force on Health Technology Assessment and a council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He served on several Swedish government commissions and was vice chairman of the board of the Karolinska Institutet.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.